Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Acute Pancreatitis I: Introduction01:25

Acute Pancreatitis I: Introduction

Acute pancreatitis is the sudden inflammation of the pancreas caused by the early activation of digestive enzymes, leading to the autodigestion of pancreatic tissue. This results in local inflammation and, in severe cases, systemic complications.EtiologyUnderstanding the underlying causes is crucial, as identifying the etiology guides treatment and anticipates complications. Acute pancreatitis can be triggered by various factors, typically grouped into the following clinical categories.Biliary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatotoxicity caused by Garcinia cambogia.

Gastroenterologia y hepatologia·2019
Same journal

ENDOSCOPIC REMOVAL OF BONE FOREIGN BODY EMBEDDED IN THE COLON.

Gastroenterologia y hepatologia·2026
Same journal

An uncommon endoscopic finding: esophageal intramural pseudodiverticulosis.

Gastroenterologia y hepatologia·2026
Same journal

Anemia and Hypoalbuminemia are Associated with Hepatic Encephalopathy and Mortality after Portal Hypertension-Related Bleeding.

Gastroenterologia y hepatologia·2026
Same journal

Optimization of a mobile application for the management of hepatitis D based on patient experience: an observational study in a hepatology cohort.

Gastroenterologia y hepatologia·2026
Same journal

Assessment of Training in Pancreatology and Biliary Diseases During Gastroenterology Residency: A National Survey by AEG-AESPANC.

Gastroenterologia y hepatologia·2026
Same journal

HEPATOCELLULAR CARCINOMA SURVEILLANCE: A PRACTICAL GUIDEBASED ON CURRENT EVIDENCE.

Gastroenterologia y hepatologia·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

[Acute on chronic liver failure].

Angels Escorsell Mañosa1, Antoni Mas Ordeig

  • 1UCI-Institut de Malalties Digestives i Metabòliques, Hospital Clínic, IDIBAPS, Universitat de Barcelona, CIBERehd, Barcelona, España. aescor@clinic.ub.es

Gastroenterologia Y Hepatologia
|December 17, 2009
PubMed
Summary
This summary is machine-generated.

Acute-on-Chronic Liver Failure (ACLF) involves severe liver deterioration, often leading to organ failure and high mortality. Liver transplantation is preferred but limited, necessitating alternative treatments for ACLF patients.

More Related Videos

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

Published on: April 28, 2020

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Related Experiment Videos

Last Updated: Jun 17, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

Published on: April 28, 2020

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Area of Science:

  • Hepatology
  • Critical Care Medicine
  • Transplantation

Background:

  • Acute-on-Chronic Liver Failure (ACLF) is a severe clinical syndrome.
  • It is characterized by acute deterioration of pre-existing liver disease, often cirrhosis.
  • ACLF presents with hepatorenal syndrome, hepatic encephalopathy, and multi-organ failure.

Purpose of the Study:

  • To define Acute-on-Chronic Liver Failure (ACLF).
  • To highlight the clinical manifestations and high short-term mortality risk.
  • To discuss treatment options, including liver transplantation.

Main Methods:

  • The abstract does not specify methods.
  • It is a descriptive overview of ACLF.

Main Results:

  • ACLF has a high incidence (40% at 5 years) in advanced cirrhosis patients.
  • This translates to approximately 4,000 European cases annually.
  • High short-term mortality is a key feature.

Conclusions:

  • Liver transplantation is the primary treatment for ACLF.
  • Organ shortage and patient morbidity/mortality necessitate exploring alternative therapies.